ABSTRACT
Introduction TB-IRIS is an important cause of morbidity and mortality in patients with HIV disease who are initiated on ART. This prospective study investigates the incidence and associated risk factors of TB-IRIS among HIV+ve patients initiating ART in North India.
Methods The study included 400 ART-naive HIV+ve patients with or without pre-existing TB. Participants underwent clinical evaluation, laboratory tests, and imaging at baseline, followed by monthly follow-ups to monitor the development of TB-IRIS over a year.
Results The study identified a TB-IRIS incidence of 9.5% among the cohort. The mean duration for TB-IRIS onset was 2.87 months, with a higher prevalence noted in patients within the first two months of ART initiation. Key baseline factors associated with TB-IRIS included low CD4 count, Hb levels, high total leukocyte count, serum creatinine, and TC levels. Notably, the CD4 count, and inflammatory markers such as CRP and ESR significantly increased from baseline to the development of TB-IRIS. The study also highlighted a significantly higher mortality rate among TB-IRIS patients compared to those without IRIS.
Conclusion The findings underscore the necessity for vigilant monitoring and early detection of TB-IRIS in HIV+ve patients undergoing ART in TB-endemic regions to mitigate morbidity and mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The Indian Council of Medical Research (ICMR), New Delhi provided funding for this work (Grant no. 80/619/2009-ECD-I). In preparation of the paper, no extramural funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
his study was approved by the Institutional ethical committee of KGMU, Lucknow, India.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study's supporting data are not publicly available due to potential privacy concerns regarding study participants. The data will be sent to the appropriate author upon reasonable request.
